Alkermes PLC (fra:8AK) Share Price

Company Profile

Business description
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Contact
1 Burlington Road
Connaught House
DublinD04 C5Y6
IRL
T: +353 17728000
https://www.alkermes.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,800

Recommended

The stocks of these high-quality companies with large market capitalizations look undervalued today.

Margaret Giles | 02 February 2026

Prices of these shares exceed our Fair Value Estimate by more than double.

Morningstar | 02 February 2026

Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.

Robert M. Almeida | 02 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,068.80	42.20	-0.46%
CAC 40	8,157.74	31.21	0.38%
DAX 40	24,663.30	124.49	0.51%
Dow JONES (US)	48,892.47	179.09	-0.36%
FTSE 100	10,250.60	27.06	0.26%
HKSE	26,775.57	611.54	-2.23%
NASDAQ	23,461.82	223.30	-0.94%
Nikkei 225	52,655.18	667.67	-1.25%
NZX 50 Index	13,412.44	10.74	-0.08%
S&P 500	6,939.03	29.98	-0.43%
S&P/ASX 200	8,778.60	42.50	-0.48%
SSE Composite Index	4,015.75	102.20	-2.48%